

Curriculum Vitae
Luke A. Probst, PharmD, BCPS, CPGx

Contact Information:

8930 Center Pointe Drive, Baldwinsville, NY 13027
4801 Lang Avenue NE, Suite 110, Albuquerque, NM 87109
505-475-0859 | 315-396-4989 (mobile)
info@lprxadvisors.com (email)



Summary:

Board Certified and Pharmacogenomics Credentialed Pharmacist with over 35 years' experience, largely in academic medical centers advancing clinical and operational pharmacy services while maintaining practice interests in pediatrics, clinical pharmacology and pharmacogenomics. Co-author of 30+ publications and numerous presentations focused on translational research. Invited presenter to local, state and national audiences. Expert consultant for medication and pharmacy practice related legal cases.

Professional Experience:

2012 – Present: LP Rx Advisors LLC (previously Probst Pharma Consulting)

Concierge Pharmacist services involving Comprehensive Medication Management and Pharmacogenomics evaluations, and general medication consulting services. Also, dba Forensic Pharmacy Experts focusing on expert consultations for litigation matters involving medications and/or pharmacy practice.

January 2023 – Present: American Society of Health System Pharmacists

Contract lead surveyor for Post-graduate Pharmacy Residency accreditation surveys.

December 2002 – December 2022: Upstate University Hospital, Syracuse NY

A career capstone spanning twenty years. I advanced pediatric pharmacy services and developed a PGY2 pediatric pharmacy residency. Rising through leadership and managerial roles, I oversaw significant expansion of inpatient and ambulatory clinical pharmacy services and residency training programs. I envisioned and established outpatient pharmacy services in 2018, which is now a 60+ FTE team generating positive margins while improving care and reducing readmissions. I served as Vice-Chair of Upstate Medical University's Institutional Review Board from 2007-2022. I led quality initiatives, spearheaded pharmacoeconomic and medication safety projects, and contributed to research-based publications. Titles held:

Director of Pharmacy Special Projects (February 2021 – December 2022)

Executive Director of Pharmacy Services (January 2017 – February 2021)

Director of Pharmacy, Downtown Campus (October 2013 – January 2017)

Associate Director of Pharmacy, Pediatric Services (October 2008 – October 2013)

Pediatric Pharmacy Specialist (December 2002 – October 2008)

Professional Experience (continued):

March 1997 – November 2002: Yale New Haven Hospital, New Haven CT

Pediatric clinical pharmacist in a 200+ bed children's hospital, actively engaged with PICU and NICU leaders. Collaborated to develop a PPAG Best Practice awarded standardized infusion protocol; conducted and presented early translational research on extended interval neonatal aminoglycoside management. As a clinical pharmacy specialist, I developed and managed several programs combining drug use policy and pharmacoeconomic initiatives.

April 1996 – March 1997: Option Care (Infucor), Danbury CT

Director of Pharmacy for a home infusion company. Responsible for clinical monitoring and operational supervision.

February 1995 – April 1996: Griffin Hospital, Derby CT

Staff pharmacist in a small community teaching hospital. Collaborated with ID physician, participated in team rounding, led pharmacy staff development efforts.

July 1994 – February 1995: Bassett Hospital, Cooperstown NY

Staff pharmacist including clinical satellite services on internal medicine unit.

August 1991 – June 1994: Medical University of South Carolina, Charleston SC

Staff pharmacist in a progressive tertiary care academic medical center; later promoted to satellite clinical pharmacist in cardiology unit.

August 1986 – July 1991: Brooks Pharmacy, Schenectady NY

Supervising pharmacist. Provided extensive patient counseling, managed department operations and accountability, fostered continuous growth and productivity.

Education and Certifications:

February 2022: FEMA Basic Incident Command System for Initial Response (IS-0200 and 0700)

May 2021: Certified Immunizer, New York State

*April 2021: Pharmacogenomics Certification, American Society of Health System Pharmacists
Basic Life Support and CPR Certification, American Red Cross*

December 2020: Board Certified Pharmacotherapy Specialist

Initially Certified December 1998.

Recertified by examination October 2005, October 2012 and December 2020

Board of Pharmacy Specialties

December 2005: Shenandoah University School of Pharmacy, Winchester VA

Doctor of Pharmacy

June 1986: Albany College of Pharmacy, Albany NY

Bachelor of Science, Pharmacy

Licensure:

New York, #I-037558 (Issued September 1986)

New Mexico #RP00009628 (Issued February 2022)

Connecticut, #8317(Inactive)

South Carolina, #7682 (Inactive)

Professional Affiliations: * denotes current membership

American College of Clinical Pharmacy

American Pharmacists Association

*American Society of Health-System Pharmacists**

Central New York Society of Health-System Pharmacists

Chapter President 2019-2021

College Fraternity Editors Association

Member of Board of Directors 1991-92

Connecticut Society of Health-System Pharmacists

*Get the Medications Right (GTMRx) Institute**

*New Mexico Pharmacists Association**

New York State Council of Health-System Pharmacists

Pediatric Pharmacy Association (formerly Pediatric Pharmacy Advocacy Group)

*Rho Pi Phi International Pharmacy Fraternity**

Hyman Wolfe Life Membership Awardee 1996

International President 1992-1995

Editor of national journal 1987-1999

Academic Highlights:

2023 – Present: University of New Mexico College of Pharmacy
Adjunct Professor of Pharmacogenomics

2003 – Present: Upstate Medical University and Upstate University Hospital
Clinical Assistant Professor Emeritus, Department of Pediatrics (2022-Present)
NURS 640 Advanced Pharmacology Course Instructor and Coordinator (2017-2018)
Vice-Chair, Institutional Review Board for the Protection of Human Subjects (2007-2022)
Clinical Assistant Professor, Departments of Medicine (2006-2022)
NURS 640 Advanced Pharmacology Lecturer in Pediatric Pharmacotherapy (2004-2013)
Preceptor for PGY1 and PGY2 Pharmacy Residents (2003-2022)
Preceptor for PharmD Candidate Rotations in Pediatric Pharmacy (2003-2013)

2016 – 2022: Binghamton University School of Pharmacy and Pharmaceutical Sciences
Adjunct Clinical Instructor in Pediatric Pharmacotherapy
Dean's Advisory Council
Pediatric Pharmacy Association Binghamton Chapter Faculty Advisor

2014 – 2021: University at Buffalo, School of Pharmacy and Pharmaceutical Sciences
Adjunct Assistant Professor

2004 – 2022: Nesbitt School of Pharmacy (Wilkes University)
Adjunct Assistant Professor

1993 – 1994: Medical University of South Carolina
Clinical Instructor in Hospital Pharmacy Practice and Administration

Publications:

- 1 *Accuracy of 4 Free Online Dosing Calculators in Predicting the Vancomycin Area Under the Concentration-Time Curve Calculated Using a 2-Point Pharmacokinetic Approach.* Belz SN, Seabury RW, Steele JM, Darko W, Miller CD, Probst LA, Kufel WD. *Annals of Pharmacotherapy.* 2022;0(0). DOI: 10.1177/10600280221117256
- 2 *A single center analysis of sugammadex and neostigmine/glycopyrrolate utilization for post-operative neuromuscular blockade reversal.* Lu H, Feldman EA, Seabury RW, Probst LA, Darko W, Miller CD. *Trends in Anesthesia and Critical Care* 2022;45:21-27. DOI: 10.1016/j.tacc.2022.07.001
- 3 *Validation of Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Factors in Predicting MRSA Community-Acquired Pneumonia at an Academic Medical Center.* Arieno J, Seabury R, Kufel W, Darko W, Miller CD, Paolo W, Cwikla G, Riddell S, Probst LA, Steele JM. *Hospital Pharmacy* 2022;57:223-229. DOI:10.1177/00185787211010149
- 4 *Prophylactic enoxaparin in critically ill trauma patients: Evaluation of the initial dose.* Agedal KJ, Feldman EA, Seabury RW, Darko W, Probst LA, Miller CD, Cwikla GM. *Hospital Pharmacy* 2022;57:540-545. DOI: 10.1177/00185787211067374
- 5 *Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.* Parsels KA, Seabury RW, Zyck S, Miller CD, Krishnamurthy S, Darko W, Probst LA, Latorre JG, Cwikla GM, Feldman EA. *American Journal of Emergency Medicine* 2022;55:16-19. DOI: 10.1016/j.ajem.2022.02.036
- 6 *Chemical and physical stability of an admixture containing cefepime and vancomycin in lactated ringer solution.* Shakeraneh P, Robinson R, Kufel WD, Tumey LN, Benjamin SR, Miller CD, Darko W, Probst LA, Seabury RW. *Hospital Pharmacy* 2021;56:338-342. DOI: 10.1177/0018578719901278
- 7 *Safety and efficacy of direct oral anticoagulant therapy in patients with cancer.* Fovel LM, Seabury RW, Miller CD, Darko W, Probst LA, Horvath L. *Journal of Pharmacy Practice* 2021;34:710-714. DOI: 10.1177/0897190019896500
- 8 *A single-center cost analysis assessing a change in vasopressin formulation.* Kelly CE, Miller C, Darko W, Mogle B, Featherly J, Marcinak R, Probst LA, Seabury R. *American Journal of Health-System Pharmacy* 2021;78:1238-1243. DOI: 10.1093/ajhp/zxab153
- 9 *Implementation of a formal pharmacy residency research certificate program.* Darko W, Seabury RW, Miller CD, Spinler SA, Probst LA, Cleary LM, Kelly C, Kufel WD. *American Journal of Health-System Pharmacy* 2021;78:436-446. DOI: 10.1093/ajhp/zxaa42

Publications (continued):

- 10 *Impact of a pharmacist-driven azithromycin de-escalation initiative for community acquired pneumonia.* Shakeraneh P, Steele JM, Seabury RW, Thomas SJ, Paolino KM, Miller CD, Probst LA, Kufel WD. *Journal of the American College of Clinical Pharmacy* 2021;4:20-26. DOI: 10.1002/jac5.1325
- 11 *Recurrent renal dysfunction secondary to probable piperacillin-tazobactam-induced acute interstitial nephritis.* Parsels KA, Seabury RW, Darko W, Probst LA, Steele JM. *Annals of Pharmacotherapy* 2021;55:133-134. DOI: 10.1177/1060028020936778
- 12 *Is it truly alpha? Incidence of thrombotic events with andexanet alfa at a single academic medical center.* Parsels KA, Seabury RW, Darko W, Probst LA, Cwikla GM, Miller CM. *Annals of Emergency Medicine* 2020;75:675-6. DOI:10.1016/j.annemergmed.2019.12.026
- 13 *Nephrotoxicity risk and clinical effectiveness of continuous versus intermittent infusion vancomycin among patients in an outpatient parenteral antimicrobial therapy program.* Shakeraneh P, Fazili T, Wang D, Gilotra T, Steele JM, Seabury RW, Miller CD, Darko W, Probst LA, Kufel WD. *Pharmacotherapy* 2020;40:357-362. DOI: 10.1002/phar.2381
- 14 *Verifying medication orders in the older population: Are we using enough caution?* Scrimenti A, Probst LA, Miller CD, Ulen KR, Noviasky J, Seabury RW. *Senior Care Pharmacist* 2020;35:182-186. DOI: 10.4140/TCP.n.2020.182
- 15 *Effect of a standardized treatment panel on hypoglycemic events in hospitalized acute hyperkalemic patients treated with intravenous regular insulin.* Zuern A, Probst LA, Darko W, Rosher P, Miller CD, Gordon L, Seabury R. *Hospital Pharmacy* 2020;55:240-245. DOI: 10.1177/001857871941035
- 16 *Evaluation of a long-acting opioid restriction policy: Does restriction reduce the need for naloxone reversal?* Fancher JL, Seabury RW, Darko W, Probst LA, Miller CD. *Hospital Pharmacy* 2020;55:32-36. DOI: 10.1177/0018578718817471
- 17 *Two high to start? Targeting a new starting dose for argatroban infusions.* White TR, Seabury RW, Darko W, Probst LA, Miller CD. *Journal of Pharmacy Technology* 2020;36:41-42. DOI: 10.1177/8755122519872698
- 18 *Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit.* Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM. *Pharmacy Practice* 2019;17:1541. DOI: 10.18549/PharmPract.2019.4.1541
- 19 *Clonidine for dexmedetomidine withdrawal in pediatric patients: A single center's experience.* Beitz ER, Seabury R, Miller CD, Darko WQ, Probst LA, Steidl KE. *Journal of Pediatric Pharmacology and Therapeutics* 2019;24:542-543. DOI: 10.5863/1551-6776-24.6.542

Publications (continued):

- 20 *Evaluation of warfarin patients with low time in therapeutic range (TTR) for transition to non-vitamin K oral anticoagulant (NOAC) therapy.* Fovel LM, Miller CD, Seabury RW, Probst LA, Horvath L. *P T* 2019;44:364.
- 21 *Andexanet alfa: Preferred treatment or therapeutic option?* Blow CA, Probst LA, Miller CD, Seabury RW. *P T* 2019;44:533.
- 22 *Evaluating the design and conduct of teaching, education, and dissemination of knowledge learning experiences: A survey of American Society of Health System Pharmacists (ASHP)-accredited postgraduate year 1 pharmacy residency programs (TEDKLE—PGY1 survey).* Darko W, Fancher JL, Feldman EA, Krasniak AE, Miller CD, Probst LA. *Journal of the American College of Clinical Pharmacy* 2019;2:544-553. DOI: 10.1002/jac5.1117
- 23 *Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium.* Kufel WD, Seabury RW, Mogle BT, Beccari MV, Probst LA, Steele JM. *American Journal of Health-System Pharmacy* 2019;76:889-894. DOI: 10.1093/ajhp/zxz070
- 24 *Impact of premix antimicrobial preparation and time to administration in septic patients.* Kufel WD, Seabury RW, Meola GM, Darko W, Probst LA, Miller CD. *CJEM Canadian Journal of Emergency Medical Care* 2018;20:565-571. DOI: 10.1017/cem.2017.33
- 25 *Changes in pharmacy residency training design between 2012 and 2017: A perspective of academic medical centers.* Krasniak A, Darko W, Miller CD, Seabury R, Probst LA. *Hospital Pharmacy* 2018;53:113-120. DOI: 10.1177/0018578717738509
- 26 *Impact of a combination antibiotic bag on compliance with Surviving Sepsis Campaign goals in emergency department patients with severe sepsis and septic shock.* Lorenzo MP, MacConaghy L, Miller CD, Meola G, Probst LA, Pratt B, Steele J, Seabury RW. *Annals of Pharmacotherapy* 2018;52:240-245. DOI: 10.1177/1060028017739324
- 27 *Price-performance ratio analysis of enteral vitamin K formulations.* Rose P, Cwikla G, Miller C, Probst L, Seabury R. *P T* 2018;43:168-170.
- 28 *Clinical feasibility of monitoring enoxaparin anti-Xa concentrations: Are we getting it right?* Kufel WD, Seabury RW, Darko W, Probst LA, Miller CD. *Hospital Pharmacy* 2017;52:214-220. DOI: 10.1310/hpj5203-214
- 29 *Pediatric drug formulations – Unintended consequences of legislation.* Probst LA, Welch TR. *New England Journal of Medicine* 2017;376:795-796. DOI: 10.1056/NEJMc1614112
- 30 *Increasing risk awareness for torsades de pointes: Evaluating QTc-prolonging medication use and ECG monitoring in hospitalized patients.* Nathan KT, Darko W, Probst LA, Miller C. *Annals of Pharmacology and Pharmaceutics* 2016;1:1002.

Publications (continued):

- 31 *Pharmacy impact on medication reconciliation in the medical intensive care unit.* Wills BM, Darko W, Seabury R, Probst LA, Miller CD, Cwikla GM. *Journal of Research in Pharmacy Practice* 2016;15:142-145. DOI: 10.4103/2279-042X.179584
- 32 *Medical management with diazepam for electrical status epilepticus during slow wave sleep in children.* Francois D, Roberts J, Hess S, Probst L, Eksioglu Y. *Pediatric Neurology* 2014;50:238-42. DOI: 10.1016/j.pediatrneurol.2013.11.002
- 33 *Evaluation of dabigatran utilization and risk among hospitalized patients.* Sidman E, Probst LA, Darko W, Miller CD. *Annals of Pharmacotherapy* 2014;48:349-53. DOI: 10.1177/1060028013513722
- 34 *Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs.* Suryadevara M, Steidl KE, Probst LA, Shaw J. *Journal of Pediatric Pharmacology and Therapeutics* 2012;17:159-165. DOI: 10.5863/1551-6776-17.2.159
- 35 *Rhabdomyolysis associated with phentermine.* Steidl KE, Darko W, Probst LA, Noviasky JA and Nasser S. *American Journal of Health-System Pharmacy* 2010;67:1929-1932. DOI: 10.2146/ajhp090395
- 36 *Mixing and compatibility guide for commonly used aerosolized medications.* Burchett DK, Darko W, Zahra J, Noviasky J, Probst L, Smith A. *American Journal of Health-System Pharmacy* 2010;67:227-30. DOI: 10.2146/ajhp080261
- 37 *Pitfalls of the application of the Modification of Diet in Renal Disease equation to drug dosing practices: A tertiary care teaching hospital experience.* Probst LA, Darko W, Smith A, Cwikla GM. *Hospital Pharmacy* 2008;43:564-70. DOI: 10.1310/hpj4307-564
- 38 *Incidence of ADEs in patients readmitted within 30 days of discharge in a tertiary care teaching hospital.* Guharoy R, Bradshaw J, Churmusi K, Baxter S, Smith A, Darko W, Probst L, LaHart A. *Formulary* 2007;42:691-694.
- 39 *Design of a safer approach to intravenous drug infusions: Failure mode effects analysis.* Apkon M, Leonard J, Probst LA, DeLizio L, Vitale RM. *Quality and Safety in Health Care* 2004;13(4):272-280. DOI: 10.1136/qshc.2003.007443
- 40 *Intravenous clonidine use in a neonate experiencing opioid-induced myoclonus.* McClain BC, Probst LA, Pinter E, Hartmannsgruber M. *Anesthesiology* 2001;95(2):549-50. DOI: 10.1097/00000542-200108000-00042

Invited Presentations:

- 1 *The Role and Value of Pharmacogenomics in Medication Management.* New Mexico Nurse Practitioner Council Spring Conference, Albuquerque NM, April 2023.
- 2 *Pharmacogenomics: Using Your Genes to Help Your Medications Fit Right.* Placitas Adult Community Education Program, Placitas NM, October 2022.
- 3 *Identifying Genetic Factors in the Latino Population for Mental Health Medication Effectiveness: The Basis Principles of Pharmacogenomics.* National Latino Behavioral Health Conference, Las Vegas NV, September 2022.
- 4 *Pharmacogenomics: The Value Proposition for Oncology Professionals.* NCODA Virtual Student Education Talk, March 2022.
- 5 *Pharmacogenomics.* Central New York Society of Health System Pharmacists Virtual Continuing Education Meeting, February 2022.
- 6 *Insights Beyond the Law: Fundamentals of Negligence in Pharmacy and Prescription Drug Cases.* National Business Institute Continuing Legal Education Live Webinar, May 2021.
- 7 *Safety and Therapeutic Challenges with Pediatric Drug Therapy.* Onondaga County Pharmaceutical Society Meeting, Syracuse NY, September 2014.
- 8 *EXCELing at Data Collection and ACCESSing Meaningful Results.* Pediatric Pharmacy Advocacy Group Research Series Live Webinar, August 2014.
- 9 *Pediatric Pharmacotherapy Update.* Pharmaceutical Society of the State of New York Mid-Winter Meeting, Saratoga Springs NY, January 2014.
- 10 *Pediatric Medication Safety: Gaps and Hurdles.* Pharmaceutical Society of the State of New York Annual Conference, Queens NY, June 2012.
- 11 *Medication Safety Across the Continuum.* New York State Council of Health Systems Pharmacists Annual Meeting, Saratoga Springs NY, May 2012.
- 12 *Pharmacology and Pharmacokinetics: The Real Reasons Why Children Aren't Just Small Adults.* Central New York Nurse Practitioner Conference, Syracuse NY, May 2011.
- 13 *Medication Safety Across the Continuum: Mind the Gap.* Pediatric Grand Rounds, Upstate Golisano Children's Hospital, Syracuse NY, October 2010.
- 14 *Prevention of Respiratory Syncytial Virus (RSV) Bronchiolitis in Infants.* Pediatric Grand Grounds, Upstate Medical University, University Hospital, October 2008.

Invited Presentations (continued):

- 15 *Pharmacokinetics Primer*. New York State Council of Health-System Pharmacists Midyear Clinical Meeting, Tarrytown NY, September 2008 and Syracuse NY, October 2008.
- 16 *The Role of a Hospital Formulary and Therapeutic Substitutions*. Noon Conference, University Hospital/Upstate Medical University, September 2008.
- 17 *Controversies in Pediatric Pharmacology*. Central New York Academy of Medicine Pharmacology Teaching Day, Whitesboro NY, April 2008.
- 18 *Analgesic Pharmacology*. Pain Resource Nurse Teaching Day, Upstate Medical University, April 2008.
- 19 *Pediatric Medication Safety and Clinical Pearls*. Medical Grand Rounds, St. Elizabeth Medical Center, Utica NY, January 2008.
- 20 *Hospital Pharmacology Program - A Model for Quality Oversight of Medication Use at an Academic Health Center*. Co-presented with David Lehmann PharmD, MD and Nancy Page RN. Pediatric Grand Rounds, Upstate Medical University, April 2007 and Nursing Grand Rounds, Upstate Medical University, July 2007.
- 21 *Pharmacologic Approaches to Pediatric Pain Control*. Symposium on Pediatric Palliative Care, University Hospital, Syracuse NY, October 2006.
- 22 *Pediatric Medication Safety and Clinical Pearls*. Children at Risk Nursing Symposium, Liverpool NY, March 2006.
- 23 *Antithrombotic Therapy in Children*. Pediatric Grand Rounds, Upstate Medical University, University Hospital, February 2006.
- 24 *Pediatric Pharmacotherapy*. Central New York Society of Health-System Pharmacists Clinical Pearls Program, Syracuse NY, January 2005.
- 25 *Every Error a Treasure: Implementation of Quality Improvement Programs from a Nonpunitive Medication Error Program*. Platform presentation at NACHRI Annual Meeting, Ft. Lauderdale FL, October 2004.
- 26 *Contemporary Issues in Pediatric Therapeutic Drug Monitoring*. Pediatric Grand Rounds, Upstate Medical University, University Hospital, March 2004.
- 27 *Gentamicin Therapy in Neonates Using an Extended Interval Dosing Paradigm*. Platform Presentation, Pediatric Pharmacy Advocacy Group Annual Meeting, Vancouver BC, October 1999.

Poster Presentations:

- 1 *Amiodarone utilization for atrial fibrillation prophylaxis in patients undergoing lobectomy.* Yuksel J, Mogle B, Feldman E, Seabury R, Miller C, Darko W, Probst L. Vizient Consortium Pharmacy Network Meeting (Virtual). December 2020.
- 2 *Meds to beds: effect on medication recovery rates and readmissions.* Chen C, Seabury R, Balotin E, Phelan C, Darko W, Probst L, Miller C. Vizient Consortium Pharmacy Network Meeting (Virtual). December 2020.
- 3 *Compliance with a new institutional alcohol withdrawal procedure: A single center's initial experience with a provider-driven protocol.* Arieno J, Seabury R, Miller CD, Darko W, Probst LA, Cwikla G. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 4 *Is it truly 'alpha'? A single academic medical center's initial experience with andexanet alfa for apixaban or rivaroxaban reversal.* Parsels K, Seabury R, Darko W, Probst L, Cwikla G, Miller C. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 5 *A single-center cost-analysis comparing two concentrations of vasopressin infusions: Is there a cost-prohibitive concentration?* Featherly J, Seabury R, Cwikla GM, Miller C, Darko W, Probst LA. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 6 *Percentage of ordered doses administered in hospitalized patients on subcutaneous unfractionated heparin or enoxaparin for venous thromboembolism prophylaxis.* Kelly C, Miller C, Darko W, Probst LA, Seabury R. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 7 *Evaluation of 4 factor prothrombin complex concentrate for coagulopathy related to liver dysfunction.* Cheruvil C, Miller CD, Feldman E, Darko W, Probst LA, Seabury R. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 8 *Evaluation of empiric alvimopan use among surgery patients.* Shtoyko AN, Seabury R, Probst LA, Darko W, Cwikla GM, Miller CD. Vizient Consortium Pharmacy Network Meeting. Las Vegas NV, December 2019.
- 9 *Evaluation of warfarin patients with low time in therapeutic range (TTR) for transition to direct oral anticoagulant (DOAC) therapy.* Fovel L, Horvath L, Darko W, Miller CD, Probst LA. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.
- 10 *Evaluation of 4-factor prothrombin complex for the reversal of direct acting anticoagulants.* Blow CA, Seabury RW, Darko W, Probst LA, Miller CD. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.

Poster Presentations (continued):

- 11 *Determining the chemical stability of a combination antibiotic bag (CAB) containing vancomycin 1.5mg/ml or 2mg/ml and cefepime 2mg/ml in 0.9% sodium chloride.* Robinson R, Seabury RW, Darko W, Probst LA, Miller CD. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.
- 12 *Determination of chemical stability of a combination antibiotic bag (CAB) with vancomycin 1mg/ml and cefepime 2mg/ml in Lactated Ringers solution.* Shakeraneh P, Seabury R, Miller C, Kufel W, Probst L, Darko W. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.
- 13 *Evaluation of argatroban dosing in non-critically ill patients with heparin-induced thrombocytopenia (HT): what is the right dose?* White TR, Seabury RW, Darko W, Probst LA, Miller CD. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.
- 14 *Chemical stability of a 50mg/ml solution of ampicillin and 0.9% sodium chloride in an elastomeric pump intended for 24 hour administration.* Maciulewicz, Seabury R, Kufel W, Darko W, Probst LA, Miller C, Bradley J, Tumey LN. Vizient Consortium Pharmacy Network Meeting, Anaheim CA, December 2018.
- 15 *Relationship Between INR Change and Either Weight-based 4-factor Prothrombin Complex Concentrate Dose or Body-Weight.* Beitz E, Seabury R, Darko W, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.
- 16 *Evaluation of Intravenous Levothyroxine Utilization and Opportunity for Additional Cost Savings with Conversion to PO Therapy.* Chang L, Darko W, Probst LA, Seabury R, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.
- 17 *Assessment of Sugammadex Utilization at an Academic Medical Center.* Fancher JL, Wong J, Seabury R, Darko W, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.
- 18 *Cost-Avoidance Evaluation of an Adjusted Volume Intravenous Vasopressin Solution.* Marcinak RR, Cwikla GM, Seabury RW, Darko W, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.
- 19 *Assessment of IV Acetaminophen Utilization After Implementation of Intravenous to Oral Protocol.* Scrimenti A, Seabury R, Darko W, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.
- 20 *Evaluation of Therapy Application and Hypoglycemic Events after Implementation of a Standardized Regular Insulin Dosing Panel for Hyperkalemia Treatment.* Zuern AM, Rosher P, Seabury RW, Darko W, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Orlando FL, December 2017.

Poster Presentations (continued):

- 21 *Description of Antibiotic Utilization for Infections Caused by Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae at a Single Academic Medical Center.* Mogle BT, Seabury R, Miller CD, Darko W, Probst LA, Steele J. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 22 *Comparison of Antifactor Xa Versus aPTT Monitoring Among Patients Receiving a Therapeutic Unfractionated Heparin Infusion.* Feldman EA, Seabury R, Darko W, Stalder B, Probst LA, Miller CD. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 23 *Hyperglycemia in Hepatitis C/HIV Co-infected Patients Receiving Hepatitis C Treatment.* Krasniak A, Blair D, Roman M, Miller CD, Seabury R, Darko W, Probst LA, Sidman E. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 24 *Evaluation of Phytonadione (Vitamin K) in an Academic Medical Center: Assessment of Utilization Trends and Cost Considerations.* Rose P, Seabury R, Probst LA, Darko W, Miller CD. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 25 *Impact of Premixed Cefepime-Vancomycin Combination Bag on Time to Antibiotic Administration in Emergency Department Patients with Severe Sepsis and Septic Shock.* Lorenzo MP, MacConaghy L, Meola G, Miller CD, Darko W, Probst LA, Seabury R. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 26 *Evaluation of Time to First Dose Antimicrobial Administration in an Academic Pediatric Hospital.* Schrader J, Seabury R, Probst LA, Darko W, Miller CD, Anderson M, Steidl K. Vizient UHC Pharmacy Council Meeting, Las Vegas NV, December 2016.
- 27 *Assessment of Inpatient Granulocyte-Colony Stimulating Factor Utilization at a Tertiary Care Academic Medical Center.* Longo DR, Burgdorf A, Miller CD, Probst LA, Darko W. ASHP Midyear Clinical Meeting. New Orleans, LA, December 2015.
- 28 *Daptomycin Utilization at an Academic Medical center: Patterns of Indication for Use and Prescribing Tendencies.* Johnson EL, Miller CD, Darko W, Probst LA, Steele J. ASHP Midyear Clinical Meeting. New Orleans, LA, December 2015.
- 29 *Evaluation of Acute Hyperkalemia Treatment at a Tertiary Care Academic Medical Center.* Machell LA, Seabury R, Probst LA, Darko W, Miller CD. ASHP Midyear Clinical Meeting. New Orleans LA, December 2015.
- 30 *Evaluation of Dextrose Utilization as a Surrogate for Insulin-Induced Hypoglycemic Events Among Hospitalized Patients.* McIver LA, Darko W, Probst LA, Miller CD. ASHP Midyear Clinical Meeting. New Orleans LA, December 2015.

Poster Presentations (continued):

- 31 *Evaluation of Intravenous Antihypertensive Use in a Tertiary Care Academic Medical Center.* Basri, DS, Darko W, Miller CD, Probst LA. ASHP Midyear Clinical Meeting. New Orleans LA, December 2015.
- 32 *Impact of Pre-mix Antibiotic Formulations and Time to Administration in Sepsis Patients.* Kufel WD, Seabury RW, Darko W, Marini AL, Probst, LA, Miller CD. ASHP Midyear Clinical Meeting. New Orleans, LA, December 2015.
- 33 *Medication Reconciliation in Patients Admitted to the Medical Intensive Care Unit.* Wills B, Darko W, Seabury R, Miller CD, Probst LA, Cwikla GC. ASHP Midyear Clinical Meeting, New Orleans LA, December 2015.
- 34 *Pharmacy Driven Therapeutic Substitution of Subcutaneous Unfractionated Heparin with Low Molecular Weight Heparin for VTE Prophylaxis.* Miller CD, Probst LA, Burgdorf A, Lehmann DF. UHC Annual Meeting. Las Vegas NV, October 2014.
- 35 *Economic outcomes of implementing an intravenous immune globulin (IVIG) prescribing and administration policy.* Rorabaugh K, Miller C, Probst L, Darko W. ASHP Midyear Clinical Meeting. Orlando FL, December 2013.
- 36 *Evaluation of Intravenous to Oral Antibiotic Conversion in Hospitalized Patients: An Opportunity for Pharmacist Intervention.* Burnett C, Probst LA, Darko W, Steele J, Miller CD. ASHP Midyear Clinical Meeting. Orlando FL, December 2013.
- 37 *Drug Use Evaluation of piperacillin/tazobactam use in an academic medical center.* Meola G, Steele J, Darko W, Probst L, Miller C. ASHP Midyear Clinical Meeting. Orlando FL, December 2013.
- 38 *Evaluation of the efficacy of an argatroban protocol in achieving target aPTT.* Keltz C, Probst LA, Darko W, Miller C. ASHP Midyear Clinical Meeting. Orlando FL, December 2013.
- 39 *Exploring the utility of restricting vancomycin to a 72 hour release period in the treatment of empiric hospital and healthcare associated pneumonia.* Sahraoui S, Steele J, Darko W, Probst L. ASHP Midyear Clinical Meeting. Orlando FL, December 2013.
- 40 *Acute and mid-term outcomes of adjuvant high dose nocturnal diazepam treatment on Electrical Status Epilepticus of Sleep.* Gunasekara RC, Francois D, Hess S, Tornabene K, Donato K, Mehrotra K, Mohan C, Probst L and Eksioglu YZ. American Epilepsy Society Annual Meeting. Washington DC, December 2013.
- 41 *Medical management of electrical status epilepticus during slow wave sleep with diazepam in pediatric patients.* Francois D, Hess S, Eskioglu Y, Probst LA. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2012.

Poster Presentations (continued):

- 42 *Medication reconciliation for children with medical complexity: a pharmacy-primary care collaborative.* Phelan C, Nimeh J, Probst LA. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2012.
- 43 *Drug Use Evaluation of Intravenous Levetiracetam at a Tertiary Care Hospital.* Garba A, Probst L, Darko W. ASHP Midyear Clinical Meeting. New Orleans LA, December 2011.
- 44 *Use and Therapeutic Substitution of Intravenous (IV) Pantoprazole in a Tertiary Care Hospital.* Seabury R, Darkow, W, Probst L, Noviasky J, Makaron A. ASHP Midyear Clinical Meeting. New Orleans LA, December 2011.
- 45 *Drug Use Evaluation of Dornase Alfa in a Tertiary Care Hospital.* Burgess J, Probst L, Darko W, Noviasky J. ASHP Midyear Clinical Meeting. New Orleans LA, December 2011.
- 46 *Vancomycin Associated Nephrotoxicity in Pediatric Patients Coincident with Higher Serum Vancomycin Trough Levels.* Probst L, Wojnowicz S, Steidl K. PPAG Annual Meeting. Memphis TN, April 2011.
- 47 *Contrast-induced nephropathy (CIN) in hospitalized pediatric patients undergoing radiologic procedures.* Roberts J, Probst L, Baxter S, Steidl K. ASHP Midyear Clinical Meeting. Anaheim CA, December 2010.
- 48 *Enoxaparin Dose Response Relationship in Pediatric Patients.* Thibert J, Probst L, Baxter S, Steidl K. ASHP Midyear Clinical Meeting. Anaheim CA, December 2010.
- 49 *Interstitial Nephritis with Oxacillin and Rifampin Therapy in Pediatric Patients.* Cavaretta M, Probst L, Baxter S, Steidl K. ASHP Midyear Clinical Meeting. Anaheim CA, December 2010.
- 50 *Treatment of Atypical Hemolytic Uremic Syndrome with Eculizumab in a 10 Month Old Child: A Case Report.* Baxter S, Steidl K, Probst LA, Listman J. PPAG Annual Meeting. St. Charles MO, October 2010.
- 51 *Cost evaluation of intravenous immune globulin (IVIG) vs. plasmapheresis in the treatment of immunologic disorders.* Kuma S, Probst L, Darko W, Baxter S. ASHP Midyear Clinical Meeting. Las Vegas, NV, December 2009.
- 52 *Pharmacist driven antimicrobial streamlining in patients with urinary tract infection in a tertiary care teaching hospital.* Whieldon A, Steele J, Darko W, Probst L, Noviasky J. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2009.
- 53 *The Impact of Remifentanyl on Mechanical Ventilation Duration in PICU Patients.* Steidl K, Probst L, Zuccaro J, Baxter S. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2009.

Poster Presentations (continued):

- 54 *Warfarin sensitivity confirmed by genetic testing due to pharmacogenetic variability.* Fredericks J, Darko W, Noviasky J, Probst L, Murray S. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2009.
- 55 *Pediatric pharmacotherapy and disease state curricula in United States pharmacy school programs: didactic and experiential exposure.* Baxter S, Probst L, Steidl K. ASHP Midyear Clinical Meeting. Las Vegas NV, December 2009.
- 56 *A Study of the Reliability of the Infusion Consistency of Prefilled Normal Saline Flush Syringes Using an Alaris Syringe Pump.* Probst L, Uhrin L, Miner B, Boevin T. Pediatric Pharmacy Advocacy Group Annual Meeting. Cleveland OH, September 2009.
- 57 *Characterization of Sedation Practices in Pediatric Intensive Care Units.* Jacobs K, Probst L, Darko W, Noviasky J. Pediatric Pharmacy Advocacy Group Annual Meeting. Cleveland OH, September 2009.
- 58 *The Development and Implementation of a Statewide Prescriber Education Program in a Medicaid System.* Wenzel M, Price M, Probst L, Marraffa J, Wellman S, Starr S, Sullivan K, Quirk M. Third Annual Umass Commonwealth Academic Medicine Conference. Westborough MA, April 2009.
- 59 *Evaluating the Use of Antipsychotic Agents in the Treatment of Delirium in the Intensive Care Unit of a Tertiary Care Teaching Hospital.* Kim E, Han C, Baxter S, Darko W, Probst L. ASHP Midyear Clinical Meeting. Orlando FL, December 2008.
- 60 *Evaluating the efficacy of Low Dose Rasburicase in the Treatment of Tumor Lysis Syndrome in a Tertiary Care Teaching Hospital.* Jacobs KE, Steele J, Probst L, Darko W. ASHP Midyear Clinical Meeting. Orlando FL, December 2008.
- 61 *Case of cross-reactivity to alteplase in a patient with a history of angioedema.* Hefty BL, Churmusi K, Noviasky J, Darko W, Probst L. ASHP Midyear Clinical Meeting. Orlando FL, December 2008.
- 62 *Optimization of clinical services via effective use of wireless technology;* Guharoy R, Stalder B, Probst L, Smith A, Darko W, Murray S, Boevin T. ASHP Midyear Clinical Meeting. Anaheim CA, December 2006.
- 63 *Incidence of adverse drug reactions on hospital readmission within 30 days of hospital discharge in a tertiary care teaching hospital;* Guharoy R, Bradshaw J, Smith A, Probst L, Darko W. ASHP Midyear Clinical Meeting. Anaheim CA, December 2006.
- 64 *A Systematic Approach to Managing Drug Shortages in an Academic Medical Center.* Probst L, Guharoy R. ASHP Midyear Clinical Meeting. New Orleans LA, December 2003.

Poster Presentations (continued):

- 65 *Redesigning intravenous infusion therapy in the pediatric intensive care unit to improve patient safety.* Vitale R, Delizio L, Leonard J, Probst L, Apkon M. Pediatric Pharmacy Advocacy Group Annual Meeting. Dana Point CA, October 2003.
- 66 *Development of Epoetin Therapy Guidelines in an Outpatient Oncology Clinic.* Abdelghamy S, Probst LA. ASHP Midyear Clinical Meeting. New Orleans LA, December 2001.

Professional Contributions and Recognition:

- 2023 – *Present: Contract Lead Surveyor*
American Society of Health System Pharmacists, Accreditation Services Division
- 2022 – *Present: Contract Medical Writer and Reviewer*
The Colibri Group
- 2020 – *Present: Manuscript Reviewer*
Journal of the American College of Clinical Pharmacy, Wiley, Inc.
- 2018 – 2022: *Guest Surveyor*
American Society of Health System Pharmacists, Accreditation Services Division
- 2018 – *Present: Manuscript Reviewer*
Peer Reviewed Reports in Medical Education Research
Society of Teachers in Family Medicine, Scholar One, Inc.
- 2015 – *Present: Manuscript Reviewer*
Journal of Pharmacy Practice, Sage Publications, Inc.
- 2015 – 2020: *Editorial Board Member and Manuscript Reviewer*
P&T Journal, MediMedia, Inc.
- 2011 – *Present: Manuscript Reviewer*
Journal of Pediatric Pharmacology and Therapeutics
- 2010 – *Present: Manuscript Reviewer*
Journal of Pediatrics, Elsevier, Inc.
- 2009 – *Present: Specialty Consultants Panel*
Pharmacist's Letter and Prescriber's Letter
- 2008 – *Present: Manuscript Reviewer*
Hospital Pharmacy, ThomasLand Publications, Inc.

Professional Contributions and Recognition (continued):

2008 – *Present: Manuscript Reviewer*

Quality and Safety in Healthcare, BMJ Publishing Group

2003: *Best Practices Award in Pediatric Pharmacy*

Redesigning intravenous infusion therapy in the pediatric intensive care unit to improve patient safety (co-author). Pediatric Pharmacy Advocacy Group Annual Meeting

Selected Media Links:

- 11/17/2020 <https://www.localsyr.com/news/local-news/upstate-hospital-purchasing-freezers-for-covid-19-vaccines-that-need-to-be-stored-at-100-below-0/>
- 1/22/2020 <https://www.localsyr.com/news/local-news/excedrin-shortage-continues-producer-cant-say-when-it-will-return/>
- 12/23/2018 <https://www.localsyr.com/news/local-news/aaa-urging-older-drivers-to-check-their-prescriptions-before-getting-behind-the-wheel/>
- 8/3/2017 <https://www.upstate.edu/hloa/2017/0803-why-it-matters-to-take-the-right-dose-of-the-right-drug-in-the-right-way.php>
- 2/1/2009 https://media.upstate.edu/pod_content/hloa/archive/2009-01-30_2-1-09-i1.mp3

-end